{"schema_version":"secwatch.filing_event.v1","accession":"0001654954-23-005946","form_type":"8-K","ticker":"PTN","cik":"0000911216","company_name":"PALATIN TECHNOLOGIES INC","filed_at":"2023-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:42.764830+00:00","generated_at":"2026-06-15T11:29:50.428125+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.35,"calibrated_materiality_score":0.35,"confidence":"high","headline":"Palatin updates on PL9643 dry eye Phase 3 lead-in data and PL8177 UC data","bullets":["PL9643 lead-in data from MELODY-1 Phase 3 shows excellent ocular tolerability and broad efficacy on dry eye signs/symptoms.","PL8177 preclinical data in rat UC models reduces colonic damage; oral formulation delivers to colon without systemic absorption.","Phase 2 study PL8177-205 for UC enrolling; interim and topline data expected in 2H2023.","KOL webinar replay with Dr. Stouch, Ousler, Raizman available on Palatin website."],"urls":{"canonical":"https://secwatch.observer/filing/0001654954-23-005946","json":"https://secwatch.observer/filing/0001654954-23-005946.json","markdown":"https://secwatch.observer/filing/0001654954-23-005946.md","text":"https://secwatch.observer/filing/0001654954-23-005946.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/911216/000165495423005946/0001654954-23-005946-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/911216/000165495423005946/ptn_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T11:29:50.428125+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}